Thursday, February 26th
The General Session will be in the
Cypress Room at the Contessa
SESSION I—GENETICS AND EPIDEMIOLOGY:
Brad Pollock, PhD
(University of Texas Health Science Center at San Antonio, TX)
“CANCER IN CHILDREN AND ADOLESCENTS IN TEXAS: A UNIQUE POPULATION?”
Louise C. Strong, MD
(The University of Texas M. D. Anderson Cancer Center, Houston, TX)
“LI FRAUMENI SYNDROME: CANCER RISK
AND RISK MODIFIERS”
Linda M. Scott, PhD
(University of Texas Health Science Center at San Antonio, TX)
“JAK2, AND THE MOLECULAR PATHOGENESIS OF DOWN SYNDROME-ASSOCIATED ACUTE LYMPHOBLASTIC LEUKEMIA”
Sharon Plon, MD, PhD
(Baylor College of Medicine, Houston, TX)
“IDENTIFICATION OF GENETIC SUSCEPTIBILITY TO CHILDHOOD CANCER THROUGH HIGH THROUGHPUT SEQUENCING OF GENES IN PARALLEL”
Ray Stallings, PhD
(Royal College of Surgeons and Our Lady's Children's Hospital, Dublin, Ireland)
“GENOME-WIDE MAPPING OF MYCN BINDING SITES IN THE NEUROBLASTOMA GENOME”
SESSION II—ANIMAL MODELS, GENES & PATHWAYS:
Scott Cameron, MD, PhD
(The University of Texas Southwestern Medical Center at Dallas)
“DISCOVERY OF DEVELOPMENTAL PATHWAYS ALTERED IN HEMATOPOIETIC DISEASE”
Charles Roberts MD, PhD
(Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA)
“RHABDOID TUMORS: EPIGENETICS, CHROMATIN
AND CANCER”
Vivienne I. Rebel, MD, PhD
(University of Texas Health Science Center at San Antonio, TX)
“MYELODYSPLASTIC SYNDROME: A VIEW FROM THE NICHE”
James Francis Amatruda, MD,PhD
(The University of Texas Southwestern Medical Center at Dallas, TX)
“THE BMP PATHWAY AND DIFFERENTIATION IN
GERM
CELL TUMORS”
Mark A. Israel, MD
(Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH)
“NEW INSIGHTS INTO CELLULAR METABOLISM: IMPLICATIONS FOR CANCER THERAPY”
Poster viewing session in the CEDAR ROOM with drinks and appetizers
included with registration fee
Friday, February 27th
The General Session will be in the Cypress Room at the ContessaSESSION III—GENOMIC INSTABILITY & DNA REPAIR:
Albert J. Fornace, Jr., MD
(Georgetown University, Washington, DC)
“MODULATION OF ONCOGENIC AND GENOTOXIC STRESS RESPONSES BY WIP1 PHOSPHATASE, THE PRODUCT OF THE PPM1D ONCOGENE WHICH IS AMPLIFIED IN PEDIATRIC TUMORS INCLUDING NEUROBLASTOMA AND MEDULLOBLASTOMA”
Matthew H. Porteus, MD, PhD
(The University of Texas Southwestern Medical Center at Dallas, TX)
“DNA DOUBLE-STRAND BREAKS: A PATH TOWARDS CAUSING CANCER, CURING CANCER AND CURING GENETIC DISEASES.”
David J. Chen, PhD
(The University of Texas Southwestern Medical Center at Dallas, TX)
“DNA-PKCS PHOSPHORYLATION IN RESPONSE TO DNA DAMAGE AND IN HEMATOPOIETIC STEM CELL MAINTENANCE”
Alexander J.R. Bishop, DPhil
(University of Texas Health Science Center at San Antonio, TX)
“A CONSERVED DAMAGE SURVIVAL NETWORK AND ITS IMPLICATIONS IN CANCER TREATMENT”
SESSION IV— SIX 15-MINUTE TALKS -to be announced
SESSION V—DISEASE MODELS & PRE-CLINICAL STUDIES:
A. Thomas Look, MD
(Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA)
“ACTIVATING MUTATIONS IN THE ALK TYROSINE KINASE PROVIDE A THERAPEUTIC TARGET IN NEUROBLASTOMA”
Rene Lawrence Galindo, MD, PhD
(The University of Texas Southwestern Medical Center at Dallas, TX)
“DROSOPHILA MUSCLE AND THAT RHABDOMYOSARCOMA ONCOPROTEIN PAX-FKHR.”
Charles Keller, MD
(University of Texas Health Science Center at San Antonio, TX)
“MUSCLING IN ON RHABDOMYOSARCOMA ORIGINS AND THERAPIES”
C. Patrick Reynolds, MD, PhD.
(Texas Tech University Health Science Center, Lubbock, TX)
“RETINOIDS IN CANCER THERAPY: SIZE DOES MATTER!”
Peter J. Houghton, PhD
(St. Jude Children’s Research Hospital, Memphis, TN)
“THE PEDIATRIC PRECLINICAL TESTING PROGRAM. RESULTS AND CHALLENGES”
){kind=link}